FTC seeks information from Par Pharmaceutical on ADHD drug Kapvay
US generic drugmaker Par Pharmaceutical said it has received an information request from the US Federal Trade Commission related to a probe into Kapvay, a drug used to treat attention deficit...To view the full article, register now.
Already a subscriber? Click here to view full article